A novel drug combination has been reported to improve survival in patients with metastatic castration-sensitive prostate cancer. However, it is unclear if this specific combination is also being used to treat other types of cancer, as some reports mention its use in metastatic colorectal cancer and breast cancer. The effectiveness of the combination in these other cancers, as well as the specific drugs involved, is not consistently reported across the outlets.